CURRICULUM VITAE

Michael Leslie Terrin, M.D., C.M., M.P.H.

Professor, Epidemiology and Public Health

University of Maryland School of Medicine

June 15, 2016

### Contact Information

660 W. Redwood Street

Howard Hall Suite 200

Baltimore, Maryland 21201

(410) 706-6139

(410) 706-4400 fax

Email: mterrin@epi.umaryland.edu

Foreign languages: French (working knowledge)

# Education

1970 B.A. Brown University Biology

1974 M.D., C.M. McGill University Medicine

1980 M.P.H. Johns Hopkins University Epidemiology

 School of Hygiene & Public Health

Post Graduate Education and Training

1974 ‑ 1975 Intern ‑ Montreal General Hospital

1975 ‑ 1976 Assistant Resident in Medicine ‑ Montreal General Hospital

1976 ‑ 1977 Resident in Medicine ‑ Montreal General Hospital

1977 ‑ 1978 Fellow in Pulmonary Medicine ‑ Montreal General Hospital

1978 ‑ 1979 Fellow in Pulmonary Medicine, Clinical ‑ Johns Hopkins Medical Institutions

1978 ‑ 1980 Fellow in Pulmonary Medicine, Clinical and Research ‑ Johns Hopkins

 Medical Institutions

1982 ‑ 1983 Attending in Internal Medicine ‑ Howard County General Hospital

### Certifications

1975 National Board of Medical Examiners ‑ Certificate No. 154911

1978 American Board of Internal Medicine ‑ Certificate No. 067081

1980 American Board of Internal Medicine, Subspecialty in Pulmonary Diseases,

 Certificate No. 067081

### Medical License

1979 State of Maryland ‑ (active)

Employment History

### Academic Appointments

1983 ‑ 2004 Adjunct Assistant Professor, Epidemiology and Preventive Medicine

 University of Maryland School of Medicine2004 Professor, part-time, Epidemiology and Preventive Medicine

 University of Maryland School of Medicine

2005 - present Professor, Epidemiology and Preventive Medicine

University of Maryland School of Medicine and (secondary appointment) Department of Medicine

2009 Tenure Awarded

Other Appointments

1967 Orderly ‑ Brooklyn State Hospital for the Mentally Ill (2 mos)

1971 ‑ 1972 Associate Editor of the Weekly Supplement to the McGill Daily

1972 ‑ 1973 Editor of the McGill Medical Journal

1972 ‑ 1974 Secretary of the Osler (Medical History) Society

1981 ‑ 1982 Medical Director - Inglenook Nursing Home

1982 - 2004 Epidemiologist, Maryland Medical Research Institute, Baltimore, MD

1987 - 1998 Vice President - Maryland Medical Research Institute (MMRI)

1989 - 1998 Vice President - Clinical Trials & Surveys Corp. (C-TASC)

1998 - 2001 President and Chief Operating Officer, Maryland Medical Research

 Institute, Baltimore, MD

2001 - 2004 President and Chief Executive Officer, Maryland Medical Research

 Institute, Baltimore, MD

2006 - present Attending Physician - University of Maryland Medical System

Professional Society Memberships

1982 - present Society for Clinical Trials

1992 - present American College of Chest Physicians

Honors and Awards

1970 Phi Beta Kappa, Member

1970 Sigma Xi, Associate Member

1973 Scarlet Key, Member

1980 Delta Omega, Member

1992 American College of Chest Physicians, Fellow

Administrative Service

Institutional Service

2005 - present Department of Epidemiology and Preventive Medicine, Seminar Committee

2005 - present Department of Epidemiology and Preventive Medicine, Appointments, Promotions and Tenure Committee (on leave June-December 2008)

2006 - present Department of Epidemiology and Preventive Medicine, Comprehensive Examination Committee

2008 - present Alternate Representative, School of Medicine Council

## International and National Service

1979 Preparation of documents on Alpha‑1‑Anti‑Trypsin Deficiency and on Chronic

 Bronchitis for the Task Force on Periodic Health Examina­tion, Health

 Services and Promotion Branch, Health and Welfare, Canada, Ottawa

1982 Consultant, Congressional Office of Technology Assessment

1985 - 1986 Program committee member, Society for Clinical Trials, Sixth Annual

 Scientific Session (1985); Seventh Annual Scientific Session (1986)

1985 Contributed Paper Session Chairman, Session IV C: Potpourri, Society for

 Clinical Trials, Sixth Annual Scientific Session

1985 Workshop Chairman, Workshop I, Insurance and Liability in Clinical Trials,

 Society for Clinical Trials, Sixth Annual Scientific Session

1989 Contributed Paper Session Chairman, Contributed Paper Session IIB, Types

 of Trial Design, Society for Clinical Trials, Tenth Annual Scientific Session

1991 Co-Director, Seventh International Symposium on Long-Term Clinical Trials,

 Cogne, Val D'Aosta, Italy

1995 Co-Director and Proceedings Editor, Eighth International Symposium on

 Long-Term Clinical Trials, Toronto, Ontario, Canada

1992 - 1997 Treasurer, Society for Clinical Trials

2000 Co-Director and Proceedings Editor, Ninth International Symposium on Long-

 Term Clinical Trials, London, U.K.

1997 - 2004 Chairman, Society for Clinical Trials Finance Committee

1980 - 2006 Guest Reviewer: American Review of Respiratory Disease, Volume 121,

 1980; Volume 124, 1981. American Journal of Epidemiology, Volume 116,

 1982: Volume 119, 1984; Volume 120, 1984; Volume 124, 1986; Volume

 137, 1993; Circulation, Volume 74, 1986; Epidemiologic Reviews, Volume

 17, 1995; Controlled Clinical Trials, Volume 16, 1995; Journal of the

 American College of Cardiology, Volume 28, 1996; American Heart Journal,

Volume 142, 2001. Chest, 2002-2006. American Journal of Cardiology, 2003. American Journal of Hematology, 2004-2007. American Journal of Physical Medicine and Rehabilitation, 2006. Journal of Orthopedic Trauma 2009-2011.

 1983 - 2006 Ad Hoc Study Section Reviewer for the National Heart, Lung and Blood

 Institute (1983, 1984, 1985, 1988, 1989, 1991, 1992, 1994, 1998, 1999,

2000, 2002); National Institute on Aging (2001, 2004, 2005, 2006); National Institute of Neurologic Diseases and Stroke (2001); National Institute of Diabetes, Digestive and Kidney Diseases (1984, 1987, 1992, 1995, 2004), the National Institute of Child Health and Human Development (1984), and the National Institute of Health General Clinical Research Centers Program (1998, 2002). Sitting Study Section (EDC-3) member for the National Institutes of Health (2002-2004).

2003 - 2005 Chairman, Data and Safety Monitoring Board, Functional Outcomes of Cleft Lip Surgery Study – Sponsored by the National Institute of Dental and Craniofacial Research (NIDCR)

2003 - 2005 Member, Data and Safety Monitoring Board, Sensory Retraining Following Orthognathic Surgery Clinical Trial – Sponsored by NIDCR

2006 - present Member, Data and Safety Monitoring Board, Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Acute Myocardial Infarction (REVEAL) – Sponsored by the National Institute on Aging (NIA)

2007 Participant, Sensible Guidelines for Clinical Trials, Washington, D.C.

2010 - present Member, National Institute on Aging (NIA) Epidemiology Study Section – C

## Local Service

1998 - 2001 Chairman, Computer Services Committee, Maryland Medical Research

 Institute (MMRI)

1998 - 2004 Member, Finance Committee, Maryland Medical Research Institute

1982 - 2004 Board of Directors, Maryland Medical Research Institute

1988 - 2004 Board of Directors, Clinical Trials & Surveys Corporation (C-TASC)

Editorial Boards

1993 - 1996 *Journal of Thrombosis and Thrombolysis*

1994 - 2003 Controlled Clinical Trials Advisory Board

## Teaching Service

Undergraduate Student Teaching

1969 Teaching Assistant ‑ The League School for Emotion­ally Disturbed Children

1969 ‑ 1970 Teaching Assistant ‑ Department of Biology, Brown University (9 mos)

1972 Research Assistant ‑ Department of Anatomy, McGill University (2 mos)

Medical Student Teaching

1976 ‑ 1977 Hosmer Teaching Fellow ‑ Montreal General Hospital

1978 ‑ 1982 Clinical Fellow ‑ The Johns Hopkins Medical Institutions

1979 - 1982 Research Fellow ‑ The Johns Hopkins Medical Institutions

1982 - present Small group session leader for various courses in Medical School for the Department of Epidemiology and Preventive Medicine (Epidemiology, Health Care Organization)

Resident and Fellow Teaching

2005 - present Department of Epidemiology and Preventive Medicine Journal Club

2005 - present Division of Gerontology Trainee Seminars

Post-Graduate Teaching

1977 - 1978 Teaching Assistant ‑ Department of Epidemiology, McGill University

First Qtr, 1980 Teaching Assistant ‑ Department of Biostatistics, The Johns Hopkins

 University School of Hygiene and Public Health

First Qtr, 1981 Teaching Assistant ‑ Department of Biostatistics, The Johns Hopkins

 University School of Hygiene and Public Health

Third Qtr, 1981 Teaching Assistant ‑ Department of Epidemiology, The Johns Hopkins

 University School of Hygiene and Public Health

Third Qtr, 1982 Teaching Assistant ‑ Department of Epidemiology, The Johns Hopkins

 University School of Hygiene and Public Health

2008-2013 PREV 803 – Clinical Trials and Experimental Epidemiology

 Course Master and Instructor (enrollment: 14 graduate students)

## Grant Support

## Ongoing Research Support

08/15/11-07/31/16 (PI: 37.5%)

Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial

(N-TA3CT)

National Institute on Aging, R01 AG037120

 Annual Direct Costs: $582,830

 Total Direct Costs: $2,914,152

09/30/09-09/29/16 (PI: 20%)

(no cost extension) Progenitor Cell Biology Consortium Administrative Coordinating Center

 National Heart, Lung, and Blood Institute, U01 HL099997

 Annual Direct Costs: $299,633

 Total Direct Costs: $2,097,432

07/01/11-06/30/16 (Co-Investigator: 5%) PI: Goldberg/Magaziner

 Claude D. Pepper Older Americans Independence Center (OAIC)

 (RC1 & RC5)

 National Institute on Aging, P30 AG028747

 Annual Direct Costs: $725,175

 Total Direct Costs: $3,625,875

09/01/10-08/31/15 (Co-Investigator: 5%) PI: Magaziner

(no cost extension) Community Ambulation Following Hip Fracture

 National Institute on Aging, R01 AG035009

 Annual Direct Costs: $330,175

 Total Direct Costs: $1,650,877

03/01/11-02/29/16 (PI: 5%) PI: Viscardi/Terrin

(no cost extension) Azithromycin to prevent BPD in Ureaplasma-infected Preterms

 NICHD, R01 HD067126

 Annual Direct Costs: $448,983

 Total Direct Costs: $2,244,915

05/01/13-04/30/18 (Co-Investigator: Contributed) PI: Magaziner/Baumgarten

Research Training in the Epidemiology of Aging

 National Institute on Aging, T32 AG000262

Annual Direct Costs: $316,802

Total Direct Costs: $1,243,688

08/01/15-05/31/17 (Co-Investigator: 2.5%) PI: Verceles

Rehabilitation, NMES and High Protein to Reduce Post ICU Syndrome

in the Elderly

National Institutes of Health, R21 AG050890

Annual Direct Costs: $125,000

Total Direct Costs: $275,000

07/01/16-12/31/20 (Co-PI: 17.5%) PI: Terrin/Pellegrini

Comparative Effectiveness of Pulmonary Embolism Prevention after Hip and Knee Replacement (PEPPER): Balancing Safety and Effectiveness

 PCORI, No Number

Annual Direct Costs: $138,491

Total Direct Costs: $699,430

## Completed Research Support

09/01/11-06/30/14 (Co-Investigator: 5%) PI: Viscardi

Effect of Lactobacillius GG on gut permeability and microbiome in VLBW neonates

 NCCAM, R34 AT006945-01

 Annual Direct Costs: $100,000

 Total Direct Costs: $283,322

05/01/08-04/30/13 (Co-Investigator: Contributed) PI: Magaziner/Baumgarten

Research Training in the Epidemiology of Aging

 National Institute on Aging, T32 AG000262

 Annual Direct Costs: $281,140

 Total Direct Costs: $1,405,700

10/01/10-09/30/12 (Co-Investigator: 5%) PI: McCombe-Waller

Combining Proximal and Distal Arm Training for Patients with Chronic Hemiparesis

 National Heart, Lung, and Blood Institute, R21 HD052125-01A1

 Annual Direct Costs: $63,337

 Total Direct Costs: $126,674

07/01/07-06/30/12 (Co-Investigator: Contributed) PI: Dischinger/Hirshon

 Injury Control and Trauma Response

 National Institutes of Health, T32 GM075767-01

 Annual Direct Costs: $193,440

 Total Direct Costs: $1,059, 660

02/12/08-01/31/12 (Co-Investigator: 2.5%) PI: Gruber-Baldini

 FOCUS Hip Fracture Transfusion Trial: Delirium & Other Cognitive Outcomes

 National Heart, Lung, and Blood Institute, R01 HL085706-01

 Annual Direct Costs: $0 (No Cost Extension)

 Total Direct Costs: $1,429,308

07/01/08-12/31/11 (Co-Investigator: 5%) PI: Netzer

 Career Development Program

 National Institutes of Health via UMB Multidisciplinary Clinical Research

 K12 RR023250-03 (Shuldiner)

 Annual Direct Costs: $140,000

 Total Direct Costs: $280,000

07/10/03-10/31/11 (PI: 10%)

 FOCUS Data Coordinating Center: Transfusion Therapy Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS)

 National Heart, Lung, and Blood Institute, R01 HL074815

 Annual Direct Costs: $389,696

 Total Direct Costs: $1,540,163

07/01/05-10/31/11 (PI: 5%)

 FOCUS-Detection of Myocardial Infarction (subcontract)

 National Institutes of Health via UMDNJ (Carson), U01 HL073958

 Annual Direct Costs: $0 (No Cost Extension)

 Total Direct Costs: $104,132

08/01/07-10/31/11 (PI: 2.5%)

Life-Threatening Pulmonary Complications of Organ Transplantation: An Investigation of the Pathogenesis of Bronchiolitis Obliterans and Its Novel Treatment with Aerosolized Liposomal Cyclosporin A (Bench to Bedside)

 National Heart, Lung, and Blood Institute, U01 HL74815-S1

 Annual Direct Costs: $25,000

 Total Direct Costs: $50,000

09/01/07-09/30/10 (Co-Investigator: 3%) PI: Viscardi

Azithromycin to Prevent BPD in Ureaplasma-Infected Preterms: Single Dose PK Study

 National Institutes of Health, R21 HD056424

 Annual Direct Costs: $157,758

 Total Direct Costs: $315,516

07/01/08-06/30/10 (Co-Investigator: 5%) PI: McCombe-Waller

Combining Proximal and Distal Arm Training for Patients with Chronic Hemiparesis

 NHLBI, R21 HD052125-01A1

 Annual Direct Costs: $175,000

 Total Direct Costs: $350,000

08/01/07-07/31/10 (PI: 4%)

 Doxycycline Treatment of Abdominal Aortic Aneurysm: Planning

 National Institute on Aging, R34 AG028684

 Total Direct Costs: $84,352

01/01/09-08/31/09 (Co-Investigator: 5%) PI: Simoni-Wastila

COPD Prevalence, Medication Use and Potential Cost Offsets for Elderly Medicare Beneficiaries

 Glaxo Smith Kline, No Number

 Annual Direct Costs: $73,175

 Total Direct Costs: $91,500

09/01/01-08/31/08 (Co-Investigator) PI: Magaziner/Yu-Yahiro Determinants of Recovery from Hip Fracture (Bone Metabolism)

National Institute on Aging, R01 AG18668

 Total Direct Costs: $2,281,816

09/30/05-07/31/06 (Co-Investigator) PI: Gruber-Baldini/Stuart

Methods of Studying Dementia Treatment and Outcomes in Observational Study (Task Order). Developing Evidence to Inform Decisions about Effectiveness: The DEcIDE Network

 Agency for Healthcare Research and Quality (TO: 290-05-0039)

 Total Direct Costs: $101,010

08/01/00-06/30/06 (Original Principal Investigator) Current PI: Thompson

 Pediatric Hydroxyurea Phase III Clinical Trial

 National Heart, Lung, and Blood Institute, N01 (HB-07160)

 Total Direct Costs: $5,158,219

 Total Costs: $5,519,294

09/10/01-08/31/05 (Co-Investigator) PI: Schulman

 Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI)

 Johns Hopkins University School of Medicine (Subcontract)

 Total Direct Costs (Estimated): $75,000/year

12/31/02-12/31/07 (Original Principal Investigator) Final PI: Barton

 MSH Patients’ Follow Up

 National Heart, Lung, and Blood Institute, N01 (HB-67129)

 Total Direct Costs: $4,173,599

09/30/99-08/31/04 (Co-Investigator) PI: Knatterud

 Occluded Artery Trial (OAT)

 National Heart, Lung, and Blood Institute, R01 (HL-62511)

04/01/01-08/31/04 (Co-Investigator) PI: Dzavik

 TOSCA-2: An Angiographic Substudy of the Occluded Artery Trial

National Heart, Lung, and Blood Institute, Subcontract from University of Alberta

10/01/02-08/31/04 (Co-Investigator) PI: Rashba

 Electrophysiologic Effects of Late PCI (OAT-EP)

National Heart, Lung, and Blood Institute, Subcontract from University of Maryland

01/01/04-08/31/04 (Co-Investigator) PI: Udelson

Myocardial Viability and Remodeling in the Occluded Artery Trial

 Subcontract from Tufts University/New England Medical Center

 National Heart, Lung, and Blood Institute, (OAT-NUC)

04/01/99-03/31/01 (PI)

A Randomized, Double-Blind, Placebo-Controlled Trial of the Presumptive Use of Fluconazole in Febrile Intensive-Care Unit Patients at Risk for Fungal Infections

 Pfizer, Inc. (Contract)

 Total Direct Costs: $40,000

06/30/95-03/31/03 (Co-Investigator) PI: Knatterud

 A Case Control Etiologic Study of Sarcoidosis (ACCESS)

 National Heart, Lung, and Blood Institute, N01 (HR-56075)

Senior Experience in Clinical Trials and Epidemiology (1995 and before)

 1. Thrombolysis in Myocardial Infarction (TIMI) Trials, Epidemiologist, Deputy Director, Coordinating Center: Randomized Trial of Two Thrombolytic Agents to Compare Efficacy in Clot Lysis: Management after Thrombolytic Therapy Comparing Routine Performance of Angiography for Revascularization Versus Angiography on Clinical Indication; and, Immediate Intravenous Beta-Blocker Therapy Versus Deferred Beta-Blocker Therapy.

 2. Prospective Investigation of Pulmonary Embolism Diagnosis, Principal Investigator, Coordinating Center: Study of V/Q Scanning and Pulmonary Angiography to Establish the Sensitivity and Specificity of V/Q Scans in the Diagnosis of Pulmonary Embolism.

 NHLBI, Total Direct Costs: $1,232,847

3. Post Coronary Artery Bypass Graft (CABG) Studies, Co-Principal Investigator, Coordinating Center: Randomized Trial with 2 X 2 Factorial Design to Compare Moderate Versus Marked LDL-Cholesterol Reduction and Low Dose Warfarin Versus Placebo in the Prevention of Saphenous Vein Bypass Graft Occlusion; and an Observational Cohort Study of Biobehavioral Status Before and After CABG Surgery.

4. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study, Co-Principal Investigator, Clinical Coordinating Center: Randomized Trial of Three Treatments (Angina-Guided Therapy, Angina-Guided Therapy Plus Ambulatory Electrocardiogram-Guided Therapy and Primary Revascularization) to Determine Their Efficacy in the Reduction of Ambulatory Electrocardiogram (AECG) Documented Ischemia and to Determine the Feasibility of a Larger Study with Clinical End Points.

5. Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) Principal Investigator, Data Coordinating Center: Randomized, Double-Blind Trial of Hydroxyurea for the Reduction of Acute Vaso-occlusive (Painful) Crises in Patients with Sickle Cell Anemia.

 NHLBI, Total Direct Costs: $1,606,821

 6. Randomized, Double-blind Controlled Clinical Trial of Ursodeoxycholic Acid in Cystic Fibrosis Associated Liver Disease, Principal Investigator, Coordinating Center: Randomized, Double-Blind Trial of Ursodeoxycholic Acid for the Improvement of Hepatobiliary Function (as Measured by Radionuclide Clearance Half-Time) in Patients with Cystic Fibrosis. NIDDH, Total Direct Costs (Approximate): $200,000

7. Rhode Island Cardiac Services Registry, Project Officer, Data Collection and Data Analysis Contractor (C-TASC): Registry of Angiography, Angioplasty and Cardiac Surgery in the State of Rhode Island. State of Rhode Island, Total Direct Costs (Approximate): $300,000

8. A Randomized Study of the Efficacy of Physician Extender-Assisted, Protocolized Care in Heart Failure Outpatients at High Risk for Hospital Readmission (CHF Team Study), Principal Investigator, Data Coordinating Center: Unblinded Trial of a Management Approach to Reduce Hospitalizations for Congestive Heart Failure.

 Private Sponsor, Total Direct Costs (Approximate): $300,000

1. Postmenopausal Hormone Therapy in Unstable Angina Study (PMHT), Principal Investigator, Data Coordinating Center: Randomized, Placebo-Controlled, Double-Blind Trial of Estrogen with and without Progesterone to Reduce Ischemia on Holter Monitoring of Post-Menopausal Women with Unstable Angina.

Publications

Peer-reviewed journal articles

1. Lala PK, Terrin ML, Lind C, and Kaizer L. Hemopoietic redistribu­tion in tumor bearing mice. Exp Hematol 1978;6:283‑298.
2. Thompson DMP, Ayeni RO, MacFarlane JK, Tataryn DN, Terrin ML, Schraufnagel D, Wilson J, and Mulder DS. A coded study of antitumor immunity to human lung cancer assayed by tube leukocyte adherence inhibition. Ann Thorac Surg 1980;31:324-331.
3. Terrin ML, and Meyer MB. Birth weight‑specific rates as a bias in the effects of smoking and other perinatal hazards. Obstet Gynecol 1981;58:636‑638. [PMID:73012427]
4. TIMI Research Group. Special Report, the Thrombolysis in Myo­cardial Infarction (TIMI) Trial, Phase I findings. New Engl J Med 1985;312:932‑936.
5. IMPACT Research Group. International Mexiletine and Placebo Antiarrhythmic Coronary Trial (IMPACT): II. Results from 24‑hour electrocardiograms. Eur Heart J 1986;7:749-759.
6. Passamani E, Hodges M, Herman M, Gross R, Chaitman B, Rogers W, Forman S, Terrin ML, Knatterud G, Robertson T, Braunwald E, for the TIMI Investigators. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Pilot Study: Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1987;10:51B-64B.
7. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber T, Bell W, Knatterud G, Robertson T, Terrin ML, for the TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI) Trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen in the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
8. Wackers FJ Th, Terrin ML, Kayden D, Knatterud G, Forman S, Braunwald E, Zaret B, for the TIMI Investigators. Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: Results of Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. J Am Coll Cardiol 1989;13:998-1005.
9. Terrin ML, Goldhaber S, Thompson BW, and the TIPE Investigators. Selection of patients with acute pulmonary embolism for thrombo­lytic therapy: The Thrombolysis in Pulmonary Embolism (TIPE) Patient Survey. Chest 1989;95:279S-281S. [PMID:2494246]
10. Terrin ML. Efficient use of end points in clinical trials: A clinical perspective. Stat Med 1990;9:155-160. [PMID:2111931]
11. The PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. Chest 1990;97:528-533.
12. The PIOPED Investigators. Value of the Ventilation/Perfusion Scan in acute pulmonary embolism: Results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). J Am Med Assoc 1990;263:2753-2759. [PMID:2332918]
13. Gore J, Sloan M, Price T, Randall AMY, Bovill E, Collen D, Forman S, Knatterud G, Sopko G, Terrin ML and the TIMI Investigators. Intracranial hemorrhage, cerebral infarction, and subdural hematoma following acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study (TIMI II Pilot and Randomized Clinical Trial). Circulation 1991;83:448-459. [PMID:1899364]
14. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, Bolli R and the TIMI Investigators. Influence of coronary collateral vessels on myocardial infarct size in man: results of Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. Circulation 1991; 83:739-746.
15. Bovill E, Terrin ML, Stump DC, Berke A, Frederick M, Collen D, Feit F, Gore J, Hillis LD, Lambrew C, Leiboff R, Mann KG, Markis JE, Pratt C, Sharkey S, Sopko G, Tracy R and Chesebro J for the TIMI Investigators. Hemorrhagic events during treatment with intravenous recombinant tissue-type plasminogen activator, heparin and aspirin in acute myocardial infarction (TIMI) Phase II Trial. Ann Intern Med 1991;115:256-265. [PMID:1906692]
16. Stein PD, Terrin ML, Hales CA, Palevsky HI, Saltzman HA, Thompson BT, and Weg JG. Clinical, laboratory, roentgenographic and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest 1991;100:598-603.
17. Stein PD, Coleman RE, Gottschalk A, Saltzman HA, Terrin ML, and Weg JG. Diagnostic utility of ventilation/perfusion lung scans in acute pulmonary embolism is not diminished by pre-existing cardiac or pulmonary disease. Chest 1991;100:604-606.
18. Stein PD, Gottschalk A, Saltzman HA and Terrin ML. Diagnosis of Acute Pulmonary Embolism in the Elderly. J Am Coll Cardiol 1991;18:1452-1457.
19. Zaret BL, Wackers FJ Th., Terrin ML, Ross R, Weis M, Slater J, Morrison J, Bourge RC, Passamani E, Knatterud G and Braunwald E. for the TIMI Investigators. Assessment of global and regional left ventricular performance at rest and during exercise after thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II Study. Am J Cardiol 1992;69:1-9.
20. Stein PD, Athanasoulis C, Alavi A, Greenspan RH, Hales CA, Saltzman HA, Vreim CE, Terrin ML and Weg JG. Complications and validity of pulmonary angiography in acute pulmonary embolism. Circulation 1992;85:462-468.
21. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevski HI, Schwartz JS, Thompson BT, Popovich J, Hobbins TE, Spera MA, Alavi A and Terrin ML. The clinical course of pulmonary embolism. N Eng J Med 1992;326:1240-1245. [PMID:1560799]
22. Stein PD, Terrin ML, Gottschalk A, Alavi A and Henry JW. Value of ventilation/perfusion scans compared to perfusion scans alone in acute pulmonary embolism. Am J Cardiol 1992;69:1239-1240.
23. Kleiman NS, Terrin ML, Mueller H, Chaitman B, Roberts R, Knatterud GL, Solomon R, McMahon RP, Braunwald E and the TIMI Investigators. Mechanisms of early death despite thrombolytic therapy: Experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Study. J Am Coll Cardiol 1992;19:1129-1135.
24. Quinn DA, Thompson BT, Terrin ML, Thrall JH, Athanasoulis CA, McKusick KA, Stein PD and Hales CA. A prospective investigation of pulmonary embolism in women and men. J Am Med Assoc 1992;268:1689-1696. [PMID:1527878]
25. Chaitman BR, McMahon RP, Terrin ML, Younis LT, Shaw LJ, Weiner DA, Frederick MM, Knatterud GL, Sopko G, Braunwald E for the TIMI Investigators. Impact of treatment strategy on predischarge exercise test in the Thrombolysis in Myocardial Infarction (TIMI) II Trial. Am J Cardiol 1993;71:131-138.
26. Taylor HA, Chaitman BR, Rogers WJ, Kern MJ, Terrin ML, Aguirre FV, Sopko G, McMahon R, Ross R, Bovill EC and the TIMI Investigators. Race and prognosis after myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. Circulation 1993;88:1484-1494.
27. Terrin ML, Williams DO, Kleiman NS, Willerson J, Mueller HS, Desvigne-Nickens P, Forman SA, Knatterud GL, Braunwald E for the TIMI Investigators. Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. J Am Coll Cardiol 1993;22:1763-1772. [PMID:8245326]
28. Becker RC, Terrin ML, Ross R, Knatterud GL, Gore JM, Braunwald E and the TIMI Investigators. Comparison of outcomes among women and men following acute myocardial infarction: The Thrombolysis in Myocardial Infarction (TIMI) Phase II experience. Ann Intern Med 1994;120:638-645. [PMID:8135447]
29. Schweiger MJ, McMahon RP, Terrin ML, Ruocco NA, Porway MN, Wiseman AH, Knatterud GL, Braunwald E for the TIMI Investigators. Comparison of patients with < 60% to > 60% diameter narrowings of the myocardial infarct related coronary artery after thrombolysis. Am J Cardiol 1994;74:105-110.
30. Outcome Measures for Clinical Trials in Cystic Fibrosis: Summary of Cystic Fibrosis Foundation Consensus Conference. J Pediatr 1995;25:395-402.
31. Gersh BJ, Chesebro JH, Braunwald E, Lambrew C, Passamani E, Solomon RE, Ross AM, Ross R, Terrin ML, Knatterud GL and the TIMI- II Investigators. Coronary artery bypass graft surgery after thrombolytic therapy in the TIMI-II Trial. J Am Coll Cardiol 1995; 25:395-402.
32. Sloan MA, Price TR, Petito CK, Randall AMY, Solomon RE, Terrin ML, Gore J, Collen D, Kleiman N, Feit F, Babb J, Herman M, Roberts WC, Sopko G, Bovill E, Forman S, Knatterud GL for the TIMI Investigators. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: The Thrombolysis in Myocardial Infarction (TIMI) II pilot and randomized clinical trial combined experience. Neurology 1995;45:649-658. [PMID: 7723950]
33. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR and the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-1322. [PMID:7715639]
34. Zaret BL, Wackers FJ, Terrin ML, Forman SA, Williams DO, Knatterud GL, Braunwald E. Value of radionuclide rest and exercise left ventricular ejection fraction to assess survival of patients following thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II Study. J Am Coll Cardiol 1995;26:73-79.
35. Bourassa M, Pepine C, Forman S, Rogers W, Dyrda I, Stone P, Chaitman B, Sharaf B, Mahmarian J, Davies R, Knatterud G, Terrin ML, Sopko G, Conti CR. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study: Effects of coronary angioplasty and coronary artery bypass graft surgery on recurrent angina and ischemia. J Am Coll Cardiol 1995, 26:606-614.
36. Charache S, Terrin ML, Moore R, Dover G, McMahon RP, Barton F, Waclawiw M, Eckert S, and the Investigators of the Multicenter Study of Hydroxyurea. Design of the Multicenter Study of Hydroxyurea. Control Clin Trials 1995;16:432-446.
37. Carson JL, Terrin ML, Duff A, Kelley MA. Pulmonary embolism and mortality in patients with COPD. Chest 1996;110:1212-1219. [PMID:8915223]
38. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O and the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Hydroxyurea and sickle cell anemia: Clinical utility of a myelosuppressive “switching” agent. Medicine 1996;75:300-326.
39. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Blood 1997;89:1078-1088.
40. Czajkowski SM, Terrin ML, Lindquist R., Hoogwerf B, Dupuis G, Shumaker S, Gray JR, Herd JA, Treat-Jacobson D, Zyzanski S, Knatterud GL for the POST CABG Biobehavioral Study Investigators. Comparison of pre-operative characteristics of men and women undergoing bypass graft surgery (The Post Coronary Artery Bypass Graft (CABG) Biobehavioral Study). Am J Cardiol 1997;79:1017-1024.
41. McMahon RP, Waclawiw MA, Geller NL, Barton FB, Terrin ML, Bonds DR, and the Investigators of the Multicenter Study of Hydroxyurea. An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). Control Clin Trials 1997;18:420-430.
42. Sloan MA, Price TR, Terrin ML, Forman S, Gore JM, Chaitman BR, Hodges M, Mueller H, Rogers WJ, Knatterud GL and Braunwald E for the TIMI Investigators. Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI II pilot and randomized clinical trial combined experience. Stroke 1997;28:1107-1114. [PMID: 9183334]
43. Terrin ML. Individual subject random assignment is the preferred means of evaluating behavioral lifestyle modification. Control Clin Trials 1997;18:500-505. [PMID:9408713]
44. Terrin ML. [Continuous intravenous epoprostenol improved survival, clinical status and hemodynamics in patients with severe primary pulmonary hypertension.](http://www.ncbi.nlm.nih.gov/pubmed/16379691) Evid Based Cardiovasc Med 1997;1:21. PubMed PMID: 16379691.
45. Carson JL, Terrin ML, Barton FB, Aaron R, Greenburg AG, Heck DA, Magaziner J, Merllino FE, Bunce G, McClelland B, Duff A and Noveck H. A pilot randomized trial comparing symptomatic versus hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion 1998;38:522-529.
46. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H and the ACCESS Research Group. Defining organ involvement in sarcoidosis: The ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:75-86.
47. Walenga JM, Hoppensteadt D, Pifarré R, Cressman MD, Hunninghake DB, Fox NL, Terrin ML, Probstfield JL and the Post CABG Studies Investigators. Hemostatic Effects of 1 mg Daily Warfarin on Post CABG Patients. J Thromb Thrombolysis 1999;7:313-318.
48. The ACCESS Research Group. Design of a Case Control Etiologic Study of Sarcoidosis (ACCESS). J Clin Epidemiol 1999;52:1173-1186.
49. Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Terrin ML, White C and the Post CABG Investigators. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial. Circulation 2000;102:157-65.
50. Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK, and the MSH Investigators. Cost-effectiveness of hydroxyurea in sickle cell anemia. Am J Hematol 2000;64:26-31.
51. Walenga JM, Hoppensteadt D, Pifarre R, Fox NL, Forman S, Hunninghake DB, Campeau L, Herd JA, Hoogwerf BJ, Hickey A, Probstfield JL, Terrin ML. The hemostatic effects of warfarin titration in Post CABG patients in comparison to placebo treatment. J Thromb Thrombolysis 2001;11:143-149.
52. Sadanandan S, Buller C, Menon V, Dzavik V, Terrin ML, Thompson B, Lamas G, Hochman J. The late open artery hypothesis - A decade later. Am Heart J 2001;142:411-421.
53. White C, Gobel FL, Campeau L, Knatterud GL, Forman SA, Forrester JS, Geller NL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Rosenberg Y, Terrin ML and the Post CABG Investigators. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the Post Coronary Artery Bypass Graft Trial. Circulation 2001;104:2660-2665.
54. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki B, Weinberger SE, Terrin ML, Knatterud GL, Cherniak R, ACCESS Research Group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-1889.
55. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, Terrin ML, Moller DR, Barnard J, Baughman RP, DePalo L, Hunninghake G, Johns C, Judson MA, Knatterud GL, McLennan G, Newman LS, Rabin DL, Rose C, Teirstein AS, Weinberger SE, Yeager H, Cherniack R. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164:2085-2091. [PMID:1173919]
56. Schulman SP, Thiemann DR, Ouyang P, Chandra NC, Schulman DS, Reis SE, Terrin ML, Forman S, de Albuquerque CP, Bahr RD, Townsend SN, Cosgriff R, Gerstenblith G. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol 2002;39:231-237.
57. Kasper EK, Gerstenblith G, Hefter G, Van Anden E, Brinker JA, Thiemann DR, Terrin ML, Forman S, Gottlieb SH. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol 2002; 39:471-480. [PMID:11823086]
58. Aversano T, Aversano LT, Passamani E, Knatterud GL, Terrin ML, Williams DO, Forman SA for the Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT). Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery. A randomized controlled trial. J Am Med Assoc 2002;287:1943-1951. [PMID:11960536]
59. Brown ST, Brett I, Almenoff PL, Lesser M, Terrin ML, Tierstein AS for the ACCESS Research Group. Recovery of cell wall-deficient organisms from blood does not distinguish between patients with sarcoidosis and control subjects. Chest 2003; 123:413-417.
60. Knatterud GL, White C, Geller NL, Campeau L, Forman SA, Domanski M, Forrester JS, Gobel FL, Herd JA, Hickey A, Hoogwerf BJ, Hunninghake DB, Terrin ML, Rosenberg Y and the Post CABG Investigators. Angiographic changes in saphenous vein grafts are predictors of clinical outcomes. Am Heart J 2003;145:262-269.
61. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin ML. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. J Am Med Assoc 2003;289:1645-1651. [PMID:12672732]
62. Herd JA, Hoogwerf BJ, Barton F, Terrin ML, Czajkowski SM, Lindquist R, Dupuis G. Heart rate and blood pressure responses to mental stress and clinical cardiovascular events in men and women after coronary artery bypass grafting: The Post Coronary Artery Bypass Graft (Post-CABG) Biobehavioral Study. Am Heart J 2003;146:273-279.
63. Lindquist R, Dupuis G, Terrin ML, Hoogwerf B, Czajkowski S, Herd JA, Barton FB, Tracy MF, Hunninghake DB, Treat-Jacobson D, Shumaker S, Zyzanski S, Goldenberg I, Knatterud GL for the Post CABG Biobehavioral Study Investigators. Comparison of health-related quality-of-life outcomes in men and women after coronary artery bypass surgery through 1 year: findings from the Post CABG Biobehavioral Study. Am Heart J 2003;146:1038-1044. [PMID:14660996]
64. Terrin ML. Fundamentals of Clinical Trials for Medical Rehabilitation. Am J Phys Med Rehabil 2003;82:S22-S25. [PMID:14502035]
65. Judson MA, Baughman RP, Thompson BW, Tierstein AS, Terrin ML, Rossman MD, Yeager H, McLennan G, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki BA, Weinberger SE, Knatterud GL, Cherniak R and ACCESS Research Group. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:204-211.
66. Terrin ML. Evaluating and implementing data and safety monitoring plans. J Investig Med 2004;52:459-463. [PMID:15651262]
67. Weinrich M, Good DC, Reding MJ, Roth EJ, Cifu DX, Silver KH, Craik RL, Magaziner J, Terrin ML, Schwartz M, Gerber L. Timing, intensity, and duration of rehabilitation for hip fracture and stroke. Report of a Workshop at the National Center for Medical Rehabilitation Research. Neurorehabil Neural Repair 2004;18:12-28. [PMID:15035960]
68. Fox NL, Hoogwerf BJ, Czajkowski S, Lindquist R, Dupuis G, Herd JA, Campeau L, Hickey A, Barton FB, Terrin ML, for the POST CABG Study Investigators. Quality of Life in POST CABG Patients: Results from the POST CABG Trial. Chest 2004;126:487-495. [PMID:15302735]
69. Newman L, Rose C, Bresnitz E, Rossman M, Barnard J, Frederick M, Terrin ML, Weinberger SE, Moller D, McLennan G, Hunninghake G, DePalo L, Baughman R, Iannuzzi M, Judson M, Knatterud G, Thompson B, Teirstein A, Yeager H, Johns CJ, Rabin D, Rybicki B, Cherniack R. A Case Control Etiologic Study of Sarcoidosis: Environmental and Occupational Risk Factors. Am J Respir Crit Care Med 2004; 170:1324-1330. [PMID:15347561]
70. Carson J, Terrin ML, Magaziner J. Anemia and postoperative rehabilitation. Can J Anesth 2003;5(6):S60-S64. [PMID:14629055]
71. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-257. [PMID:15642562]
72. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, Hare JM, Gerstenblith, G. L-Arginine Therapy in Acute Myocardial Infarction: The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial. J Am Med Assoc 2006;295:58-64. [PMID:16391217]
73. Dupuis G, Kennedy E, Lindquist R, Barton FB, Terrin ML, Hoogwerf BJ, Czajkowski SM, Herd JA, for the Post CABG Biobehavioral Study Investigators. Coronary Artery Bypass Graft Surgery and Cognitive Performance. Am J Crit Care 2006;15(5):471-479. [PMID:16926368]
74. Carson JL, Terrin ML, Magaziner J, Chaitman BR, Apple FS, Heck DA, Sanders D, for the FOCUS Investigators. Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS). Transfusion 2006;46:2192-2206. [PMID:17176334]
75. Eisenstein EL, Collins R, Cracknell BS, Podesta O, Reid ED, Sandercock P, Shakhov Y, Terrin ML, Sellers MA, Califf RM, Granger CB, Diaz R. Sensible approaches for reducing clinical trial costs. Clinical Trials 2008;5:75-84. [PMID:18283084]
76. Baxter BT, Terrin ML, Dalman RL. Medical Management of Small Abdominal Aortic Aneurysms. Circulation 2008;117:1883-1889. [PMID:18391122]
77. Quinn CC, Gruber-Baldini AL, Shardell M, Weed K, Clough SS, Peeples M, Terrin ML, Bronich-Hall L, Barr E, Lender D. Mobile Diabetes Intervention Study: Testing a Personalized Treatment/Behavioral Communication Intervention for Blood Glucose Control. Contemporary Clinical Trials 2009;30:336-346. [PMID:19250979]
78. Netzer G, Liu X, Harris AD, Edelman BB, Hess JR, Shanholtz C, Murphy DJ, Terrin ML. Transfusion Practice in the Intensive Care Unit: A Ten-Year Analysis. Transfusion 2010, 50:2125-2134. [PMID:20553436]
79. Hassan H, Othman AA, Eddington ND, Duffy L, Xiao L, Waites KB, Kaufman DA, Fairchild KD, Terrin ML, Viscardi RM. Pharmacokinetics, Safety, and Biologic Effects of Azithromycin in Extremely Preterm Infants at Risk for Ureaplasma Colonization and Bronchopulmonary Dysplasia. J Clin Pharmacol 2011, 51:1264-1275. [PMID:21098694]
80. Quinn CC, Shardell MD, Terrin ML, Barr EA, Ballew SH, Gruber-Baldini AL. [Cluster-Randomized Trial of a Mobile Phone Personalized Behavioral Intervention for Blood Glucose Control.](http://www.ncbi.nlm.nih.gov/pubmed/21788632) Diabetes Care 2011, 34:1934-1942. [PMID:21788632]
81. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, Horney RA, and Magaziner J for the FOCUS Investigators. Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery. N Engl J Med 2011; 365:2453-2462. [PMID:22168590]
82. Turner PL, Lumpkins K, Gabre J, Lin MJ, Liu X, and Terrin ML. Pregnancy Among Women Surgeons: Trends Over Time. Arch Surg 2012; 147:474-479. [PMID:22351877]
83. Verceles AC, Silhan L, Terrin ML, Netzer G, Shanholtz C, Scharf SM. Circadian rhythm disruption in severe sepsis: the effect of ambient light on urinary 6-sulfatoxymelatonin secretion. Intensive Care Med 2012; 38:804-810. [PMID:22286671]
84. Verceles AC, Liu XL, Terrin ML, Scharf SM, Shanholtz C, Harris A, Ayanleye A, Parker A, Netzer G. Ambient Light Levels and Critical Care Outcomes. Journal of Critical Care. Epub Jul 2, 2012. [PMID:22762935]
85. Ruiz A, Hernandez I, Ronsende-Roca M, Gonzalez-Perez A, Rodriguez-Noriega E, Ramirez-Lorca R, Mauleon A, Moreno-Rey C, Boswell L, Tune L, Valero S, Alegret M, Gayan J, Becker JT, Real LM, Tarraga L, Ballard C, Terrin ML, Sherman S, Payami H, Lopez OL, Mintzer JE, Boada M. Exploratory analysis of 7 Alzheimer’s disease genes: Disease Progression, Neurobiol Aging 2013;34(4):1310.e1-7. doi: 10.1016/j.neurobiolaging. 2012. 08.014. Epub Oct 1, 2012. [PMID: 23036585]
86. Horenstein RB, Mitchell BD, Post WS, Leutjohann D, Bergmann K, Ryan KA, Terrin ML, Shuldiner AR, Steinle NI. The *ABCG8 G574R* variant, serum plant sterol levels, and cardiovascular disease risk in the Old Order Amish. Arterioscler Thromb Vasc Biol 2013;33(2):413-9. doi: 10.1161/ATVBAHA.112.245480. Epub Dec 13, 2012. [PMID: 23241408]
87. Qian J, Simoni-Wastilla L, Langenburg P, Rattinger GB, Zuckerman IH, Lehmann S, Terrin M.

Effects of Depression Diagnosis and Antidepressant Treatment on Mortality in Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease. J Am Geriatr Soc 2013; 61:754-761. doi:10.1111/jgs.12220. Epub 2013 Apr 25. [PMID: 23617752]

1. Viscardi RM, Othman AA, Hassan HE, Eddington ND, Abebe E, Terrin ML, Kaufman DA, Waites KB. [Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.](http://www.ncbi.nlm.nih.gov/pubmed/23439637) Antimicrob Agents Chemother 2013; 57:2127-2133. doi: 10.1128/AAC.02183-12. Epub 2013 Feb 25. [PMID: 23439637; PMCID: PMC3632913]
2. Gruber-Baldini A, Marcantonio E, Orwig D, Magaziner J, Terrin M, Barr E, Brown JP, Paris B, Zagorin A, Roffey DM, Zakriya K, Blute MR, Hebel JR, Carson JL. Delirium Outcomes in a Randomized Trial of Blood Transfusion Thresholds. JAGS 2013. J Am Geriatr Soc 2013; 61:1286-1295.
3. Qian J, Simoni-Wastila L, Rattinger GB, Lehmann S, Langenberg P, Zuckerman IH, Terrin M. [Associations of depression diagnosis and antidepressant treatment with mortality among young and disabled Medicare beneficiaries with COPD.](http://www.ncbi.nlm.nih.gov/pubmed/23871313) Gen Hosp Psychiatry 2013; 35:612-618. doi: 10.1016/j.genhosppsych.2013.06.005. Epub 2013 Jul 18. [PMID: 23871313]
4. Afshar M, Smith GS, Terrin ML, Barrett M, Lissauer ME, Mansoor S, Jeudy J, Netzer G. Blood Alcohol Content, Injury Severity and Acute Respiratory Distress Syndrome. J Trauma Acute Care Surg 2014;76:1447-1455. [PMCID:PMC4034145]
5. Quinn C, Sareh PL, Shardell ML, Terrin ML, Barr EA, Gruber-Baldini A. Mobile Diabetes Intervention for Glycemic Control: Impact on Physician Prescribing. J Diabetes Sci Technol. Epub February 5, 2014. DOI: 10.1177/1932296813514503.
6. Quinn CC, Shardell MD, Terrin ML, Barr EA, Park D, Shaikh F, Guralnik JM, Gruber-Baldini AL. Mobile Diabetes Intervention for Glycemic Control in 45 to 64 Year Old Persons with Type 2 Diabetes. J Applied Gerontol. 2016; 35:227-243. Epub August 6, 2014. DOI: 10.1177/ 0733464814542611. [PMID 25098253]
7. Liu X, Post WS, McLenithan J, Terrin ML, Magder L, Zeb I, Budoff M, Mitchell BD. Determinants of intrathoracic adipose tissue and associations with cardiovascular disease risk factors in Amish. Nutrition, metabolism, and cardiovascular diseases: NMCD 2014; 24(3):286-293. doi: 10.1016/j.numecd.2013.9.015. [PMCID: PMC4109402]
8. [Merchan LM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Merchan%20LM%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Hassan HE](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hassan%20HE%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Terrin ML](http://www.ncbi.nlm.nih.gov/pubmed/?term=Terrin%20ML%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Waites KB](http://www.ncbi.nlm.nih.gov/pubmed/?term=Waites%20KB%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Kaufman DA](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kaufman%20DA%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Ambalavanan N](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ambalavanan%20N%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Donohue P](http://www.ncbi.nlm.nih.gov/pubmed/?term=Donohue%20P%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Dulkerian SJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Dulkerian%20SJ%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Schelonka R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Schelonka%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Magder LS](http://www.ncbi.nlm.nih.gov/pubmed/?term=Magder%20LS%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Shukla S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Shukla%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Eddington ND](http://www.ncbi.nlm.nih.gov/pubmed/?term=Eddington%20ND%5BAuthor%5D&cauthor=true&cauthor_uid=25385115), [Viscardi RM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Viscardi%20RM%5BAuthor%5D&cauthor=true&cauthor_uid=25385115). Pharmacokinetics, Microbial Response, and Pulmonary Outcomes of Multidose Intravenous Azithromycin in Preterm Infants at Risk for Ureaplasma Respiratory Colonization. [Antimicrob Agents Chemother](http://www.ncbi.nlm.nih.gov/pubmed/?term=Viscardi+and+Pharmacokinetics+2014) 2015; 59(1):570-578. doi: 10.1128/AAC.03951-14. Epub 2014 Nov 10.
9. Albrecht JS, Marcantonio ER, Roffey DM, Orwig D, Magaziner J, Terrin M, Carson JL, Barr E, Brown JP, Gentry EG, Gruber-Baldini AL; Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair Cognitive Ancillary Study Investigators. [Stability of postoperative delirium psychomotor subtypes in individuals with hip fracture.](http://www.ncbi.nlm.nih.gov/pubmed/25943948) J Am Geriatr Soc 2015;63:970-976. doi: 10.1111/jgs.13334. Epub 2015 May 4. [PMID: 25943948; PMCID: PMC4439362]
10. Timofte I, Terrin M, Barr E, Sanchez P, Kim J, Reed R, Britt E, Ravichandran B, Rajagopal K, Griffith B, Pham S, Pierson RN 3rd, Iacono A. Belatacept for Renal Rescue in Lung Transplant Patients. Transpl Int 2016; 29:453-463. doi: 10.1111/tri.12731. [PMID:26678245]
11. Baxter TB, Matsumura J, Curci J, McBride R, Blackwelder WC, Liu X, Larson L, and Terrin ML. Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial(N-TA3CT): Design of a Phase IIb, Placebo-Controlled, Double-Blind, Randomized Clinical Trial of Doxycycline for the Reduction of Growth of Small Abdominal Aortic Aneurysm. Contemporary Clinical Trials 2016; 48:91-98. doi: 10.1016/j.cct.2016.03.008. [Epub ahead of print]

Abstracts

1. Lala PK and Terrin ML. Hemopoiesis in the ascites tumor bearing mouse. Anat Rec 1973; 175:366‑367.
2. Terrin ML. Berkson's bias and Simpson's paradox are the same fallacy in the analysis of cross‑classified categorical data. Control Clin Trials 1984;5:301.
3. Handy C and Terrin ML. Visual image data processing in randomized clinical trials. Control Clin Trials 1985;6:238.
4. Prud'homme G, and Terrin ML. Design issues in a diagnostic trial. Control Clin Trials 1985; 6:230.
5. Terrin ML, Forman S. Compound end points in clinical trials. Control Clin Trials 1986; 7:250.
6. Bovill E, Stump D, Tracy R, Collen D, Robertson T, Terrin ML, Mann K for the TIMI Investigators. Dose response relationship of rt-PA infusion to induction of systemic fibrin(ogen)olyses in the Thrombolysis in Myocardial Infarction (TIMI) Trial. Blood 1987; 70(Suppl 1):367a.
7. Thompson B, Handy C, Terrin ML. Imputing Missing Values Under Order Restrictions. Control Clin Trials 1988;9:262.
8. Bovill E, Stump D, Tracy R, Collen D, Robertson T, Terrin ML, Chesebro I, Feit F, Lambrew C, Mann K. for the TIMI Investigators. Dose response relationship of rt-PA infusion to induction of systemic fibrin(ogen)olysis in the NHLBI Thrombolysis in Myocardial Infarction (TIMI-II) Trial. J Am Coll Cardiol 1989;13:198A.
9. Wackers F J Th, Zaret BL, Terrin ML, Ross R, Bourge R, Kayden DS, Morrison J, Slater J, Weiss M, Braunwald E. Impact of Invasive and Conservative Thrombolytic Strategies on Global and Regional Left Ventricular Function: Results of the TIMI II Trial. Circulation 1989;80:II-312.
10. Zaret BL, Wackers F J Th, Terrin ML, Ross R, Weiss M, Slater J, Morrison J, Bourge R, Kayden DS, Braunwald E. Exercise Ventricular Function Following Thrombolysis: Effect of Invasive Versus Conservative Strategies in the TIMI II Trial. Circulation 1989; 80:II-608.
11. Gore J, Sloan M, Price T, Terrin ML, Bovill E, Collen D, Knatterud G, Randall AMY, Sopko G, and the TIMI Investigators. Intracranial hemorrhage after rt-PA and heparin for acute myocardial infarction - the TIMI II Pilot and Randomized Trial combined experience. J Am Coll Cardiol 1990;15:15A.
12. Sloan MA, Price TA, Randall AM, Solomon RE, Terrin ML and the TIMI Investigators. Intracerebral hemorrhage after rt-PA and heparin for acute myocardial infarction: the TIMI II pilot and randomized trial combined experience. Stroke 1990;21:182.
13. Becker R, Ross R, Terrin ML, Knatterud G, Braunwald E and the TIMI Investigators. Gender-related differences in clinical outcome following acute MI: The TIMI II experience. Circulation 1990;82:III-667.
14. Gersh BJ, Chesebro JH, Braunwald EG, Kirklin JW, Lambrew C, Passamani EG, Solomon RE, Ross AM, Ross R, Terrin ML. Knatterud GL and the TIMI-II Investigators. Coronary bypass surgery after thrombolytic therapy in the TIMI-II Trial. Circulation 1990;82:III-361.
15. Kleiman N, Terrin ML, McMahon R, Solomon R, Roberts R and the TIMI Investigators. Early death despite thrombolysis and beta blockade: Experience from the TIMI-II Study. Circulation 1990;82:III-432.
16. Schweiger MJ, McMahon R, Ruocco NA, Gianelly RE, Hafer JG, Whitfield SS, Terrin ML and the TIMI Investigators. Prognosis of patients with non-significant stenosis in the infarct related artery post thrombosis. Circulation 1990;82:III-250.
17. Tracy RP, Bovill EG, Terrin ML, Collen DJ, Mann KG for the TIMI Investigators. Coagulation inhibitor values in myocardial infarction compared to those in normals. J Am Coll Cardiol 1991;17:145A.
18. Stein PD, Fulkerson WJ, Hales CA, Kelley MA, Leeper KV, Palevsky HI, Popovich J, Saltzman HA, Terrin ML, Thompson BT, Vreim CE, Weg JG, Clinical assessment of acute pulmonary embolism in patients with no prior cardiac or pulmonary disease. J Am Coll Cardiol 1991;17:146A.
19. Zaret BL, Wackers FJ, Terrin ML, Ross R, Knatterud GL, Braunwald E and the TIMI Investigators. Does left ventricular ejection fraction following thrombolytic therapy have the same prognostic impact described in the prethrombolytic era? Results of the TIMI II Trial. J Am Coll Cardiol 1991;17:214A.
20. Quinn DA, Terrin ML, Thompson BT, Thrall JH, Athanasoulis CA, McKusick KA, Stein PD and Hales CA. Pulmonary embolism (PE) in women in the prospective investigation of PE diagnostics (PIOPED) Circulation 1991;84:II-1202.
21. Terrin ML, Ross, R, Forman S, Wackers F, Zaret B and Knatterud G. The importance of counting all the patients. Control Clin Trials 1991;12:686.
22. Terrin ML, Frederick M, Thompson BW, Knatterud GL and the TIMI Investigators. Observational analyses with time dependency and missing values in the Thrombolysis in Myocardial Infarction (TIMI) II clinical trial. Control Clin Trials 1992;13:383.
23. McMahon RP, Terrin ML, Barton FB for the MSH Study Group. Rank statistics for analysis of a clinical trial with multiple events per patient: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). Control Clin Trials 1992;13:441.
24. Carson JL, Kelley MA and Terrin ML. The clinical course of pulmonary embolism, the authors reply. N Engl J Med 1992;327:957-958.
25. Czajkowski SM, Lindquist R, Hoogwerf B, Dupuis G, Shumaker SA, Terrin ML, Knatterud GL for the POST CABG Studies Investigators. Women coronary artery bypass graft (CABG) surgery patients are sicker and have fewer social and economic resources than men. Circulation 1992;86(Suppl):I-674.
26. Sloan MA, Price TR, Terrin ML, Forman S for the TIMI Investigators. Ischemic Cerebral Infarction after rt-PA and Heparin Therapy for Acute Myocardial Infarction: The TIMI-II Pilot and Randomized Trial Combined Experience. Ann Neurol 1992;32:238.
27. Terrin ML, Williams DO, Kleiman NS, et al. Two-and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. J Am Coll Cardiol 1993;21:176A.
28. Quinn DA, Thompson BT, Terrin ML, et al. Subselecting patients at risk for pulmonary embolism, the authors reply. J Am Med Assoc 1993;269:987.
29. Multicenter Study of Hydroxyurea (MSH). Preventing pain in sickle cell anemia (HB SS): Baseline data from patients in a hydroxyurea trial. Blood 1993;82(Suppl 1):356a.
30. Swerdlow PS, Smith WR, Barton F, Ballas SK, Terrin ML and the MSH Study Group. Measurement of pain in sickle cell anemia. Blood 1993;82(Suppl 1):475a.
31. Forman S, Terrin ML, Ra K, Bowden G, Giro R. A treatment allocation system which preserves randomization schedules and intent-to-treat. Control Clin Trials 1994;15:101S.
32. Barton F, Terrin ML, Charache S, Koshy M, Swerdlow P, Ewart C, McMahon R and the MSH Investigators. Measurement of health quality of life in the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Control Clin Trials 1994;15:120S.
33. Randall AMY, Lindquist RD, Terrin ML. A comparison of methods used to summarize responses on the functional status questionnaire (FSQ) unscaled responses vs. scaled scores. Control Clin Trials 1995;16:93S.
34. Charache S, Dover GJ, Moore RD and Terrin ML. Hydroxyurea and sickle cell crisis, the authors reply. N Engl J Med 1995;333:1009.
35. Barton F, Moore R, Terrin ML, Charache S, Koshy M. Treatment guesses by patients and investigators in a double-blind clinical trial. Control Clin Trials 1996;17:40S.
36. Barton F, Terrin ML, Moore R, McMahon RP, Charache S. Ascertainment of the primary end point in the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). Control Clin Trials 1996;17:67S.
37. McMahon RP, Waclawiw MA, Geller NL, Barton FB and Terrin ML. An extension of stochastic curtailment for incompletely reported and ascertained data on recurrent

outcomes: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH). Control Clin Trials 1996;17:72S.

1. Handy C, Barton F, Moore R, McMahon RP, Eckert S, Terrin ML, Dover G, Charache S. Dose titration in the Multicenter Study of Hydroxyurea in sickle cell anemia (MSH). Control Clin Trials 1996;17:92S.
2. Thompson B, Forman S, Terrin ML. The analysis of transformed count data in clinical trials. Control Clin Trials 1997;18:131-32S.
3. Sadanandan S, Lamas G, Buller C, Dzavik V, Terrin ML, Steingart R, Mark D, Thompson B, Wagner G, Kopecky S, Wong SC, Hochman JS. Angiographic characteristics and management of occluded infarct related artery following acute myocardial infarction - findings from Registry of the Open Artery Trial. J Am Coll Cardiol 1999;33(Suppl A):379A.
4. Terrin ML, Barton FB, Bonds D, Waclawiw M, Steinberg M, Koshy M, Ramirez G Kutlar A. Observational follow-up after clinical trial closure of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Control Clin Trials 1999;20:41S.
5. Terrin ML, Forman S, Fick S, Clarke E, Gross R, Gerstenblith G, Gottlieb S, Brinker J, Kasper E. Facsimile copy (Fax) transmission data entry direct from clinical sites in the CHF Team Study. Control Clin Trials 1999;20:78S.
6. Steinberg MH, Barton F, Castro O, Koshy M, Eckman J, Terrin ML. Risks and benefits of hydroxyurea (HU) in adult sickle cell anemia. Effects at 6- to 7-years. Blood 1999;94:644-645a.
7. Terrin ML, Barton F, Barton B. Interim monitoring of safety and efficacy outcomes in randomized clinical trials. Control Clin Trials 2000;21:46S.
8. Steinberg MH, Barton F, Castro O, Ramirez G, Bellevue R, Terrin ML. Hydroxyurea (HU) is associated with reduced mortality in adults with sickle cell anemia. Blood 2000;96:485a.
9. Terrin ML, Thompson BW, Barton FB. Selection of primary end point and analysis for diseases and treatments that involve multiple organ systems. Control Clin Trials 2001; 22:67S.
10. Walenga JM, Hoppensteadt D, Fox NL, Forman SA, Hunninghake DB, Herd JA, Hoogwerf BJ, Hickey A, Probstfield JL, Terrin ML. Hemostatic markers in Post CABG patients treated with warfarin or placebo and two lipid-lowering strategies. Blood 2003;102(11):810A.
11. Kiel DP, Barton BA, Birge SJ, Magaziner J, Terrin ML, Zimmerman SI. HIP PRO: A multicenter, randomized, controlled trial of hip protectors in nursing home residents. Journal of the American Geriatric Society 2003;51:S52-S53.
12. Kiel DP, Barton BA, Birge SJ, Magaziner J, Terrin ML, Zimmerman SI. HIP PRO: A multicenter, randomized, controlled trial of hip protectors in nursing home residents. Abstract submitted to the American Society for Bone and Mineral Research Annual Meeting, Minneapolis, MN, September 19-23, 2003.
13. McCarthy WF, Forman SA, Barton BA, Schulman SP, Terrin ML. A method for an unbiased assessment of treatment effect in the vascular interaction with age in myocardial infarction (Vintage MI) Clinical Trial. Clin Trials J 2004;2:242.
14. Brandon AE, McCarthy WF, Barton FB, Terrin ML. Vital status determination of patients’ lost to follow-up in the multicenter study of hydroxyurea in sickle cell anemia (MSH) patients’ follow-up study. Clin Trials J 2004;2:244.
15. Gruber-Baldini A, Marcantonio E, Orwig D, Magaziner J, Terrin ML, Carson JL, Barr E, Brown J, Bergmann M, & Okafor M, for the FOCUS CAS Investigators. Factors Associated with In-hospital Delirium after Hip Fracture. Paper presentation at the annual meeting of the Gerontological Society of America, Atlanta, GA. Abstract published in The Gerontologist, 49, October 2009.
16. Netzer G, Liu X, Harris A, Edelman B, Hess J, Shanholtz C, Murphy DJ, Terrin ML. Transfusion Practice in the Intensive Care Unit: A Ten-Year Analysis. Annual Meeting of the American Society of Hematology, 2009.
17. Carson JL, Terrin ML, Magaziner J, Chaitman, B, Sanders D Impact of Transfusion Triggers on Postoperative Myocardial Infarction or Death. Circulation 2009;120:2155.
18. Carson JL, Terrin ML, Magaziner J, Sanders D, Cook DR, Hildebrand K. Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS): The Principal Results. ASH Annual Meeting Abstracts 2009; 114:LBA-6.
19. Netzer G, Liu X, Terrin ML, Shanholtz C, Harris AD, Verceles A, Iwashyna TJ. Substantial Changes in Several Outcomes with a Multi-Component Intervention in a Tertiary Care Medical Intensive Care Unit. American Thoracic Society Scientific Session, 2010.
20. Netzer G, Liu X, Terrin ML, Shanholtz C, Harris AD, Verceles A, Iwashyna TJ. Effect of a Multi-component Intervention on Sedation Use. American Thoracic Society Scientific Session, 2010.
21. Gruber-Baldini A, Marcantonio ER, Orwig D, Magaziner J, Terrin ML, Carson J, Barr E, Hebel JR. FOCUS Cognitive Ancillary Study: Randomized Clinical Trial of Blood Transfusion Thresholds on Delirium Severity. Poster presentation during the Presidential Poster Session at the annual meeting of the American Geriatric Society, Orlando, FL, May 12-15, 2010. Abstract to be published in the Journal of the American Geriatrics Society.
22. Terrin ML, Magaziner J, Carson J, Horney RA, Lefever A. Clinical Site Variability in Adherence and Intermediate Outcomes. Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS) paper presentation at the Society of Clinical Trials Annual Meeting, Baltimore, MD, May 18, 2010.
23. Jolapalem P, Todd N, Britt EJ, Terrin ML, Peterman C, and Iacono A. Steroid-Sparing Effect of Mycophenolate Mofetil in Pulmonary Sarcoidosis. Accepted for poster presentation at the American Thoracic Society’s International Meeting, May 19, 2010, New Orleans, LA.
24. Quinn CC, Gruber-Baldini AL, Shardell, M, Terrin ML, Barr E, Shaik F, Park D, Brazda M. (2012). Mobile Diabetes Intervention for Blood Glucose Control: Challenging Age Misconceptions. Paper presentation at the 65th Annual Meeting of the Gerontological Society of America, November 16-18, 2012, San Diego, CA. Abstract published in The Gerontologist, 52, October 2012.
25. Gruber-Baldini A, Marcantonio E, Barr E, Brown JP, Orwig D, Terrin ML, Magaziner J, Carson JL. (2012). Dementia andDelirium as Predictors of Recovery in Walking after Hip Fracture. Poster presentation at the 65th Annual Meeting of the Gerontological Society of America, November 16-18, 2012, San Diego, CA. Abstract published in The Gerontologist, 52, October 2012.

Letters

1. Terrin ML. Letter to the Editor, Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;124:763‑764.
2. Terrin ML. Letter to the Editor, Electrocardiographic, enzymatic and scintigraphic criteria for diagnosis of acute myocardial infarc­tion. Am J Cardiol 1986;57:897.
3. Wackers F J Th, Zaret BL, Kayden DS, Terrin ML, Knatterud G, Forman S, Braunwald E. Letter to the Editor, Streptokinase or tissue plasminogen activator and left ventricular function after myocardial infarction. New Engl J Med 1989;321:687-688.
4. The PIOPED Investigators. Letter to the Editor, The diagnosis of pulmonary embolism. J Am Med Assoc 1990;264:2624.
5. Quinn DA, Hales CA, Thompson BT, Terrin ML. Letter to the Editor, Subselecting patients at risk for pulmonary embolism. J Am Med Assoc 1993;269:987.
6. Charache S, Dover GJ, Moore RD, Terrin ML. Letter to the Editor, Hydroxyurea and sickle cell crisis. New Engl J Med 1995;333:1009.
7. Steinberg MH, Barton F, Terrin ML, Waclawiw M, Bonds D. Letter to the Editor, Long-term use of hydroxyurea for sickle cell anemia. J Am Med Assoc 2003;290:754.

Other Scientific Contributions - Invited Presentations

1. Case presentation, Maryland Thoracic Society, Nineteenth Annual Scientific Session, Linthicum, Maryland, February 1979.
2. Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED), presentation to the American College of Chest Physicians, 53th Annual Scientific Assembly, Atlanta, Georgia, October 1987.
3. Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED), presentation to the American Thoracic Society Annual Scientific Sessions, Las Vegas, Nevada, May 1988.
4. Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED), presentation to the Society of Nuclear Medicine, Annual Scientific Sessions, San Francisco, California, June 1988.
5. Selection of Patients with Acute Pulmonary Embolism for t-PA Therapy: The Thrombolysis in Pulmonary Embolism (TIPE) Patient Survey. Presented to the American College of Chest Physicians, 54th Annual Scientific Assembly, Anaheim, California, October 1988.
6. Efficient Use of Endpoints in Clinical Trials: A Clinical Perspective. Presented to the Cost and Efficiency in Clinical Trials Workshop, National Heart, Lung, and Blood Institute, Bethesda, Maryland, January 1989.
7. Surrogate Markers - General Considerations and Guiding Principles. Presented to the Dupont Merck Science Commitment Conference, College Park, Maryland, June 1992.
8. Clinical Trial Design. Presented to the Consensus Conference: Clinical Outcomes for Evaluation of New CF Therapies. Cystic Fibrosis Foundation, Rockville, Maryland, December 1992.
9. Clinical Trials in Behavioral Medicine (Part 1): Study Design and Methodology. Workshop presented with Genell L. Knatterud, Ph.D. and Norma Lynn Fox, Ph.D. The Third International Congress of Biobehavioral Medicine. Amsterdam, The Netherlands, July 1994.
10. Timing, Intensity and Duration of Rehabilitation for Hip Fracture and Stroke. NIH (National Center for Medical Rehabilitation Research, NCMRR) Workshop Invited Presenter: Clinical Trials for Rehabilitation, Bethesda, Maryland, August 2001.
11. Clinical Trials in Medical Rehabilitation: Enhancing Rigor and Relevance. Kessler Medical Rehabilitation, Research and Education Corporation; NIH (National Center for Medical Rehabilitation Research, NCMRR) Workshop Invited Presenter, Parsippany, New Jersey, November 2002.
12. Data and Safety Monitoring. Tufts University Sackler School of Medicine Workshop Presenter: Evaluating and Implementing Data and Safety Monitoring Plans, Boston, Massachusetts, December 2002.
13. Coordination of Multisite Studies: Strategies for Success. Workshop presented with Ruth L. Lindquist, Ph.D. and Byron Hoogwerf, M.D. Invited Presenter. American Heart Association Annual Scientific Session, New Orleans, Louisiana, November 2004.
14. Anemia in the Elderly: Clinical Trials Opportunities. NIH (National Institute on Aging, NIA) Workshop Participant, Bethesda, Maryland, October 2006.
15. Musculoskeletal Research Conference. NIH (National Center for Medical Rehabilitation Research, NCMRR). Participant. Bethesda, Maryland, January 2006.
16. Critical Illness and Critical Care in Older Patients. NIH (National Institutes on Aging, NIA) Workshop, Invited Presenter, Bethesda, Maryland, September 2007.
17. Sensible Guidelines in Clinical Trials. McMaster University/Oxford University/Duke Clinical Research Institute Participant and Panel Member, Washington DC, December 2007.
18. Asthma in the Elderly. NIH (National Institute on Aging, NIA, National Institute of Allergy and Infectious Disease, NIAID) and NHLBI (National Heart, Lung, and Blood Institute) Workshop, Invited Participant, September 2008.